Ralliant (NYSE:RAL) Sets New 1-Year High – Here’s Why

Ralliant Corporation (NYSE:RAL) shares hit a new 52-week high on Tuesday . The stock traded as high as $64.04 and last traded at $63.96, with a volume of 59398 shares. The stock had previously closed at $61.03.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Morgan Stanley lifted their price objective on Ralliant from $45.00 to $68.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. TD Cowen lifted their price objective on Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 20th. Truist Financial reissued a “buy” rating and issued a $68.00 price objective (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. Evercore assumed coverage on Ralliant in a report on Tuesday. They issued an “outperform” rating and a $80.00 price objective for the company. Finally, Citigroup lifted their price objective on Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $67.30.

Ralliant Stock Performance

The company has a 50-day moving average price of $52.09 and a two-hundred day moving average price of $49.57. The stock has a market capitalization of $6.99 billion and a P/E ratio of -5.71. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm had revenue of $534.60 million for the quarter. The company’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities analysts expect that Ralliant Corporation will post 2.64 earnings per share for the current year.

Ralliant Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th will be given a dividend of $0.05 per share. The ex-dividend date is Monday, June 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Ralliant’s dividend payout ratio is currently -1.83%.

Hedge Funds Weigh In On Ralliant

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RAL. Danske Bank A S purchased a new position in Ralliant during the fourth quarter worth about $25,000. V Square Quantitative Management LLC purchased a new position in Ralliant during the fourth quarter worth about $26,000. Allworth Financial LP grew its position in Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after buying an additional 293 shares in the last quarter. Palisade Asset Management LLC purchased a new position in Ralliant during the third quarter worth about $26,000. Finally, BOKF NA purchased a new position in Ralliant during the third quarter worth about $29,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.